33 skidoo as Anaptysbio exiting I.V. for subcu in eczema bid

Anaptysbio Inc.'s phase IIa interim data win with intravenous (I.V.) ANB-020, the antibody targeting interleukin-33 (IL-33) for eczema, touched off speculation about competitors working in the same pathway, as the firm's shares climbed 101 percent to close Tuesday at $70.41.